Doxercalciferol

SKU: orb1301062

Description

Doxercalciferol is a synthetic analog of vitamin D2 used in research to study secondary hyperparathyroidism and metabolic bone disorders. It functions by suppressing parathyroid hormone synthesis and secretion, making it a key tool for in vitro and in vivo investigations into mineral metabolism and renal osteodystrophy.

Research Area

Metabolism Research

Key Properties

• CAS Number: 54573-75-0
• MW: 412.65
• Purity: 99.69% (May vary between batches)
• Formula: C₂₈H₄₄O₂
• SMILES: C[C@@]12[C@](\C(=C\C=C\3/C(=C)[C@@H](O)C[C@H](O)C3)\CCC1)(CC[C@@]2([C@@H](/C=C/[C@@H](C(C)C)C)C)[H])[H]
• Target: Others,Vitamin
• Solubility: DMSO:4.15 mg/mL (10.06 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.42 mM);Ethanol:20.6 mg/mL (49.92 mM)

Bioactivity

• In Vivo:
  Doxercalciferol (100 or 300 pg/g b.w.) normalizes serum calcium and parathyroid hormone (PTH) levels in nephrectomy treated mice. Doxercalciferol (300 pg/g b.w.) significantly reduces osteitis fibrosa in nephrectomy treated mice. Doxercalciferol results in significant decrease in cardiac hypertrophy and improves cardiac function in rats fed a high salt (HS) diet. Doxercalciferol treatment leads to a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level in rats fed a high salt (HS) diet. Doxercalciferol also significantly reduces the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. Doxercalciferol decreases proteinuria, podocyte injury, mesangial expansion, and extracellular matrix protein accumulation in Diet-induced obesity (DIO) mice. Doxercalciferol also decreases macrophage infiltration, oxidative stress, proinflammatory cytokines, and profibrotic growth factors in DIO mice. Doxercalciferol also prevents the activation of the renin-angiotensin-aldosterone system including the angiotensin II type 1 receptor and the mineralocorticoid receptor in DIO mice. Doxercalciferol combined with Losartan most effectively prevents albuminuria, restored glomerular filtration barrier structure, and dramatically reduces glomerulosclerosis in a dose-dependent manner in mice. Doxercalciferol combined with Losartan virtually prevents morphological and molecular changes in diabetic kidneys of mice.

Storage & Handling

• Storage: Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, Hectorol, Doxercalciferol, 1.alpha.-Hydroxyvitamin D2, 1α-hydroxyvitamin D2, 1alpha-hydroxyvitamin D2, 1a-hydroxyvitamin D2, TSA 840, TSA840, TSA-840, VD/VDR, Vitamin D, Vitamin D receptor

Compound Identifiers

PubChem CID

5281107